DACS
TEVA icon

Dymon Asia Capital (Singapore)’s Teva Pharmaceuticals TEVA Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03M Sell
60,000
-40,000
-40% -$1.33M 0.09% 121
2026
Q1 		$3.01M Buy
+100,000
New +$3.22M 0.31% 93

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s TEVA Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) reduced its Teva Pharmaceuticals (TEVA) stake by 40% in Q2 2026, selling an estimated $1.33M and leaving 60,000 shares worth $2.03M. The position accounts for 0.09% of the portfolio, ranked #121.

Dymon Asia Capital (Singapore) first reported a position in TEVA in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.01M in Q1 2026. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Dymon Asia Capital (Singapore) held 60,000 shares of Teva Pharmaceuticals worth $2.03M as of Q2 2026.
  • Dymon Asia Capital (Singapore) sold 40,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.33M.
  • Teva Pharmaceuticals made up 0.09% of Dymon Asia Capital (Singapore)'s portfolio in Q2 2026, its #121 holding.
  • Dymon Asia Capital (Singapore) first reported a position in Teva Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Dymon Asia Capital (Singapore)'s Teva Pharmaceuticals position peaked at $3.01M in Q1 2026.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.